Stifel Initiates Coverage On Vistagen Therapeutics with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has initiated coverage on Vistagen Therapeutics (NASDAQ:VTGN) with a Buy rating and set a price target of $12.
November 14, 2023 | 5:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Paul Matteis has initiated coverage on Vistagen Therapeutics with a Buy rating and a price target of $12.
Initiation of coverage by an analyst with a Buy rating typically generates positive sentiment among investors, potentially driving the stock price up in the short term. The price target of $12 suggests a significant upside from the current trading price, indicating a bullish outlook for the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100